Results 71 to 80 of about 13,727 (197)

Effect of sacubitril/valsartan on the occurrence of cardiac arrhythmias and the risk of sudden cardiac death in heart failure: A meta-analysis of randomized controlled trials

Frontiers in Cardiovascular Medicine, 2022
BackgroundSacubitril/valsartan therapy reduced the risks of death and of hospitalization for heart failure (HF). HF and cardiac arrhythmias have shared physiological mechanisems.
Xue-Hui Liu, Xue-Hui Liu, Guan-Ling Wang, Qiang Xu, Qiang Xu, Lei Zhang, Lei Zhang, Hong-Jun Liu, Hong-Jun Liu   +8 more
doaj   +1 more source

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source

Natriuretic Peptides in the Cardiovascular System. Multifaceted Roles in Physiology, Pathology and Therapeutics [PDF]

, 2019
The natriuretic peptides (NPs) family includes a class of hormones and their receptors needed for the physiological control of cardiovascular functions. The discovery of NPs provided a fundamental contribution into our understanding of the physiological ...
Rubattu, Speranza, Volpe, Massimo
core   +1 more source

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié, Richard Isnard, Françoise Pousset, Clémence Grave, Jacques Blacher, Amélie Gabet   +5 more
wiley   +1 more source

What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan? [PDF]

, 2017
AIMS: The PARADIGM-HF trial showed that sacubitril-valsartan, an ARB-neprilysin inhibitor, is more effective than enalapril for some patients with heart failure (HF).
Clark, Andrew L., Cleland, John G. F., Dierckx, Riet, Kazmi, Syed, MacNamara, Alexandra, Pellicori, Pierpaolo, Shah, Parin, Urbinati, Alessia, Zhang, Jufen   +8 more
core   +3 more sources

Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction

ESC Heart Failure, 2021
Aims Ivabradine and sacubitril/valsartan are second‐line therapies for patients with heart failure and reduced ejection fraction (HFrEF) based on guideline recommendations. We aimed to evaluate the synergistic effects of these two medications.
Ying‐Hsiang Lee, Po‐Lin Lin, Wei‐Ru Chiou, Jin‐Long Huang, Wen‐Yu Lin, Chia‐Te Liao, Fa‐Po Chung, Huai‐Wen Liang, Chien‐Yi Hsu, Hung‐Yu Chang   +9 more
doaj   +1 more source

Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator

ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh, Katharina Koepsel, Julia W. Erath, Thomas Kuntz, Norbert Klein, Boldizsar Kovacs, Firat Duru, Ardan M. Saguner, Christian Blockhaus, Dong‐In Shin, Fabienne Kreimer, Michael Gotzmann, Hendrik Lapp, Thomas Beiert, Assem Aweimer, Andreas Mügge, Christel Weiß, Ibrahim El‐Battrawy, Ibrahim Akin   +18 more
wiley   +1 more source

A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)

Scientific Reports
Sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor, is widely used to treat heart failure. Despite its efficacy, sacubitril/valsartan inevitably causes adverse events such as hypotension, renal dysfunction, hyperkalemia, and
Ning Wang, Haijun Wang, Ying Chen, Yanfeng Wang   +3 more
doaj   +1 more source

Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats

ESC Heart Failure, Volume 12, Issue 2, Page 1304-1315, April 2025.
Parts of the figure were drawn by using pictures from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/). Abstract Aims Sacubitril/valsartan (Sac/Val) is used for treatment of heart failure. The effect of Sac/Val on regional dysfunction
Einar Sjaastad Nordén, Bård Andre Bendiksen, Kaja Knudsen Bergo, Emil Knut Stenersen Espe, Gary McGinley, Almira Hasic, Ida Marie Hauge‐Iversen, Hege Katrin Ugland, Xin Shen, Michael Frisk, Nishani S. Mabotuwana, William E. Louch, Rizwan I. Hussain, Lili Zhang, Ivar Sjaastad, Alessandro Cataliotti, Geir Christensen   +16 more
wiley   +1 more source

Contemporary characteristics and outcomes in chagasic heart failure compared with other nonischemic and ischemic cardiomyopathy [PDF]

, 2017
Background: Chagas’ disease is an important cause of cardiomyopathy in Latin America. We aimed to compare clinical characteristics and outcomes in patients with heart failure (HF) with reduced ejection fraction caused by Chagas’ disease, with other ...
Claudio R. Gimpelewicz, Efraín A. Gómez, Felipe Martinez, Felix Ramires, Jean L. Rouleau, John J.V. McMurray, Karl Swedberg, Kenneth Dickstein, Lars Køber, Li Shen, Luis Eduardo Echeverría, Luiz Carlos Bodanese, Michael R. Zile, Milton Packer, null null, Pardeep S. Jhund, Scott D. Solomon, William T. Abraham   +17 more
core   +3 more sources